Completed PHASE1 INTERVENTIONAL 2-arm NCT03082053

A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

A Phase Ib Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Sponsor: ASLAN Pharmaceuticals

Conditions Advanced or Metastatic Biliary Tract Cancer Advanced or Metastatic Solid Tumors

Updated 8 times since 2017 Last updated: Jun 27, 2018 Started: Jan 31, 2017 Primary completion: Dec 7, 2017 Completion: Jun 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced or Metastatic Biliary Tract Cancer and Advanced or Metastatic Solid Tumors and is currently completed. ASLAN Pharmaceuticals leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — May 2023 [monthly]

Completed PHASE1
Jul 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE1
Jan 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Apr 2017 — Jan 2018 [monthly]

Recruiting PHASE1

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ASLAN Pharmaceuticals

Data source: ASLAN Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan